secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001728117-23-000050
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH
------------------------------------------------------------------------

- Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.
- Cash, equivalents and marketable securities of $201.9M as of March 31, 2023; expected to fund operations through at least 12 months.
- Phase 3 registrational trial of seralutinib in PAH planned for 3Q23; FDA and EMA feedback on key design elements received.
- Operational restructuring: headcount reduced by over 25%; all other clinical/preclinical programs terminated.
- Initial open-label extension data from TORREY study expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/0001728117-23-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/goss-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001728117-23-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer